These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37169309)

  • 1. Effect of a lifestyle intervention to prevent weight gain at initiation of insulin pump therapy in type 2 diabetes: A randomized, controlled, multicentre trial.
    Bétry C; Lablanche S; Carvalho M; Amougay H; Du-Boullay H; Crand A; Lamy C; Borges L; Gorain S; Borel JC; Borel AL
    Diabetes Res Clin Pract; 2023 Jun; 200():110698. PubMed ID: 37169309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
    Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
    Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised controlled trial investigating the effect of an intensive lifestyle intervention v. standard care in adults with type 2 diabetes immediately after initiating insulin therapy.
    Barratt R; Frost G; Millward DJ; Truby H
    Br J Nutr; 2008 May; 99(5):1025-31. PubMed ID: 18197995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.
    Niswender K; Piletic M; Andersen H; Conradsen Hiort L; Hollander P
    Diabetes Obes Metab; 2014 Feb; 16(2):186-92. PubMed ID: 24112375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.
    Aronson R; Reznik Y; Conget I; Castañeda JA; Runzis S; Lee SW; Cohen O;
    Diabetes Obes Metab; 2016 May; 18(5):500-7. PubMed ID: 26854123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.
    Paul SK; Shaw JE; Montvida O; Klein K
    Diabetes Obes Metab; 2016 Dec; 18(12):1244-1252. PubMed ID: 27502528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus.
    Asche CV; Bode B; Busk AK; Nair SR
    Diabetes Obes Metab; 2012 Jan; 14(1):47-57. PubMed ID: 21834876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain.
    Riebenfeld D; Spirk D; Mathis A; Villiger L; Gerber PA; Gasser UE; Lehmann R
    Swiss Med Wkly; 2015; 145():w14114. PubMed ID: 25741640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).
    de Wit HM; Vervoort GM; Jansen HJ; de Grauw WJ; de Galan BE; Tack CJ
    Diabetologia; 2014 Sep; 57(9):1812-9. PubMed ID: 24947583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
    Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
    Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study.
    Dale J; Martin S; Gadsby R
    Prim Care Diabetes; 2010 Jul; 4(2):85-9. PubMed ID: 20392683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.
    Davies MJ; Donnelly R; Barnett AH; Jones S; Nicolay C; Kilcoyne A
    Diabetes Obes Metab; 2009 Dec; 11(12):1153-62. PubMed ID: 19930005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
    Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
    Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial.
    van Dieren S; Kengne AP; Chalmers J; Beulens JW; Davis TM; Fulcher G; Heller SR; Patel A; Colagiuri S; Hamet P; Mancia G; Marre M; Neal B; Williams B; Peelen LM; van der Schouw YT; Woodward M; Zoungas S
    Diabetes Obes Metab; 2014 May; 16(5):426-32. PubMed ID: 24251579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming clinical inertia in insulin initiation in primary care for patients with type 2 diabetes: 24-month follow-up of the Stepping Up cluster randomised controlled trial.
    Manski-Nankervis JA; Furler J; O'Neal D; Ginnivan L; Thuraisingam S; Blackberry I
    Prim Care Diabetes; 2017 Oct; 11(5):474-481. PubMed ID: 28705697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol.
    Bally L; Thabit H; Tauschmann M; Allen JM; Hartnell S; Wilinska ME; Exall J; Huegel V; Sibayan J; Borgman S; Cheng P; Blackburn M; Lawton J; Elleri D; Leelarathna L; Acerini CL; Campbell F; Shah VN; Criego A; Evans ML; Dunger DB; Kollman C; Bergenstal RM; Hovorka R
    BMJ Open; 2017 Jul; 7(7):e016738. PubMed ID: 28710224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.